# Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

> **NCT07092605** · EARLY_PHASE1 · ENROLLING_BY_INVITATION · sponsor: **AgelessRx** · enrollment: 150 (estimated)

## Conditions studied

- Longevity
- Quality of Life
- Mood
- Inflammation
- Immune Health
- Pain Management
- Weight Management
- Alertness

## Interventions

- **DRUG:** GLP-1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07092605
- **Lead sponsor:** AgelessRx
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-11-01
- **Primary completion:** 2025-11-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07092605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07092605, "Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07092605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*